CRIVICIN GRISEOFULVIN TABLET B.P. 500 mg
Each uncoated tablet contains
Griseofulvin B.P. 500mg
CRIVICIN-500 is an fungistatic antibiotic derived from a specie of penicillium and used for the treatment of superficial mycosis.
CRIVICIN-500 is active in vitro against various species of microsporum, Epiderniophyton and Trichophyton. It has no effect on bacteria or another genera of fungi, such as candida albicans (‘thrush fungus’); Aspergillas and Malassezia furfur (pityriasis Versicolor).
CRIVICIN-500 is deposited in the keratin precursor cells and has a greater affinity for diseased tissues. It enables newly-formed keratin of the skin, hair and nails to resist attack by fungi.
CRIVICIN-500 is effective against the dermatophytes causing ringworm (tinea) infection of the skin, hair and nails including microsporum canis, Trichophyton rubrum and T. Verucosum. It is generally given for such infections that involve the scalp, hair, nails and skin and which do not respond to topical treatment.
DOSAGE AND ADMINISTRATION
Dosage should be taken after meals, otherwise absorption is likely to be inadequate.
Normally 500-1000 mg (1-2 tablets) daily, but not less than 10 mg/kg body weight daily. A single dose daily is often satisfactory but divided doses may be more effective in patients who respond poorly.
Usually 10mg/kg body weight daily in divided doses.
The duration of treatment depends upon the thickness of keratin at the site of infection. 2-6 weeks for infection of hair and skin, 6-9 months for infections of the finger nails and 12-18 months for the infection of the toe nails.
CRIVICIN-500 is contraindicated in patients with porphyria, liver failure, and in individuals with history of hypersensitivity to Griseofulvin.
Concurrent treatment with CRIVICIN-500 may reduce the effectiveness of oral contraceptives, so additional contraceptive precautions should be taken during CRIVICIN-500 treatment and for a month after stopping it. As there is no evidence of its safety in human pregnancy (Griseofulvin is teratogenic in animals and some case reports suggest that it produces human foetal abnormalities). CRIVICIN-500 should not be used during pregnancy.
Griseofulvin decreases the activity of warfarin-type anticoagulants so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after CRIVICIN-500 therapy.
Barbiturates usually depress Griseofulvin activity and concomitant administration may require a dosage adjustment of the antifungal agent.
Potentiates alcohol, effect producing effect like trachycardia and flush.
When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria and rarely angioneurotic edema.
Other side effects, reported occasionally, are gastric discomfort, headache, dizziness and insomnia, dryness of the mouth, an altered sensation of taste. Proteinuria and leucopenia have been reported rarely. Administration of the drug should be discontinued if granulocy topenia occurs.
STORE IN COOL DRY PLACE.
PROTECT FROM DIRECT LIGHT.
KEEP ALL MEDICINE OUT OF REACH OF CHILDREN.
CRIVICIN-500 tabs are supplied in Blister pack of 20 Tablets.
NAFDAC Reg. No.: A4-6246
Manufactured in China by
Nantong Jinghua Pharmaceutical Co, Ltd.
9 Xingtai Road, Gangzha Zone Nantong Jiangsu China 226005
CLARION MEDICALS LTD.
23, Afolabi Lesi Street, llupeju,